---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062020"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:16:32.776493+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma reports Q3 2023 cash of $105.6M; Phase 3 sarcoidosis study enrollment to complete early Q2 2024

## Summary
- Cash, cash equivalents and investments totaled $105.6M as of September 30, 2023.
- Phase 3 EFZO-FIT study in pulmonary sarcoidosis expects enrollment completion early Q2 2024; positive DSMB safety review.
- Phase 2 EFZO-CONNECT study in systemic sclerosis-ILD dosed first patient.
- R&D expenses were $10.3M, G&A $2.6M, collaboration revenue $0.4M from Kyorin agreement.
- Updated cash runway guidance: sufficient through BLA filing for efzofitimod in sarcoidosis.

## SEC filing metadata
- accession: 0000950170-23-062020
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/0000950170-23-062020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/life-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062020
- JSON: https://secwatch.observer/filing/0000950170-23-062020.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062020.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC updated its third quarter of 2023 guidance (reaffirmed).
  - Period: third quarter of 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On November 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023062020/0000950170-23-062020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.